Sahajanand Medical Technologies Sets ₹475.48 Crore IPO at ₹344

Sahajanand Medical Technologies Limited has set its ₹475.48 crore initial public offering at a price band of ₹327 to ₹344 per share, with bidding scheduled from October 15 to October 19, 2026 and listing planned for October 23, 2026. The offering gives investors access to a medical-device maker focused on vascular intervention and structural heart products.

What are the Sahajanand Medical Technologies IPO terms?

Sahajanand Medical Technologies has announced a book-built public issue of 13,822,116 equity shares, aggregating to ₹475.48 crore at the stated offer price of ₹344 per share. The equity shares have a face value of ₹1 each, with the offer price including a premium of ₹343 per share.

The price band is ₹327 to ₹344 per share. The lot size is 43 shares, and the stated minimum investment at the upper end of the price band is ₹14,792. The issue information also states that a retail investor can apply for up to 13 lots, or 559 shares, requiring ₹192,296 at the upper price band.

The offer is scheduled to open on Thursday, October 15, 2026, and close on Monday, October 19, 2026. The provided IPO details identify qualified institutional buyers, retail individual investors and non-institutional investors as participating investor categories. No retail discount is stated.

When will Sahajanand Medical Technologies shares be allotted and listed?

Sahajanand Medical Technologies is scheduled to finalise allotment on October 21, 2026, followed by refund initiation and demat credit on October 22, 2026. Its shares are scheduled to list on both BSE and NSE on October 23, 2026.

The company is identified by BSE symbol 545001, NSE symbol SMT and ISIN INE356Y01018 in the supplied fact sheet. The listing timeline places the proposed market debut four days after the issue closes, subject to completion of the stated allotment and demat processes.

What does Sahajanand Medical Technologies make?

Sahajanand Medical Technologies develops Class III and Class C/D medical devices, with an emphasis on vascular intervention and structural heart solutions. These classifications indicate that the company operates in higher-complexity medical-device categories covered by the information provided.

Its vascular intervention portfolio includes coronary stents and coronary balloons used in the diagnosis or treatment of blood-vessel diseases. Its structural heart portfolio includes trans-catheter aortic valve implantation, or TAVI, products and occluders used to address defects or abnormalities in the structure of the heart.

Other products named in the company profile include renal stents, peripheral drug-coated balloon catheters and trading products. The company also trades in and distributes medical devices and implants, along with surgical, hospital, pharmaceutical, dental, laboratory, orthopaedic and traumatology products and equipment.

How does Sahajanand Medical Technologies operate across markets?

Sahajanand Medical Technologies serves India, Europe, the rest of Asia Pacific, Latin America, and the Middle East and Africa, according to the company profile. This geographic footprint places its products across multiple international medical-device markets rather than only the domestic market.

The company has three manufacturing facilities, including two in India and one in Thailand. It also operates two research and development facilities in India and Thailand. These sites support its stated R&D-driven approach to vascular intervention and structural heart medical devices.

The company was founded by Dhirajlal Kotadia in 2001 and is headquartered in Surat, India. It was incorporated on September 30, 2001, and converted into a public limited company following a shareholder special resolution dated April 27, 2021. A fresh certificate of incorporation was issued on May 7, 2021 by the Registrar of Companies, Gujarat at Ahmedabad.

Why is the IPO relevant for investors and the medical-device sector?

Sahajanand Medical Technologies brings a specialised cardiovascular medical-device business to the public markets, covering vascular intervention, structural heart and related segments. For investors, the disclosed offer terms provide the key entry parameters: a ₹327 to ₹344 price band, a 43-share lot and a proposed October 23 listing date.

The company operates in products that include coronary stents, balloons, TAVI systems and occluders. These are used in cardiovascular procedures and related treatment settings, making product development, manufacturing capability and distribution reach central elements of the business described in the fact sheet.

The supplied materials refer to the offering as a public book-building issue and state it is a fresh issue of 1.38 crore shares. A separate offer description refers to an offer for sale. The cited aggregate issue size, price range, share count and listing timetable are consistent across the key IPO details supplied, while investors should refer to the final offer documents for the definitive issue structure.

What should investors monitor before the proposed listing?

Sahajanand Medical Technologies investors can monitor the bidding period from October 15 to October 19, the allotment date of October 21 and the proposed BSE and NSE listing on October 23. These dates set the immediate sequence for applicants after submitting bids within the announced price range.

Investors may also assess the business through the company’s product mix and operating network. Its portfolio spans vascular intervention, structural heart and other medical devices, while its manufacturing and R&D operations are located across India and Thailand. The supplied information does not provide financial performance figures, valuation metrics or subscription data, so those items cannot be assessed from this fact sheet.

Conclusion

Sahajanand Medical Technologies is bringing a ₹475.48 crore medical-device IPO to the market at ₹327 to ₹344 per share. Its business is focused on Class III and Class C/D devices, including coronary intervention products, TAVI products and occluders, supported by manufacturing facilities in India and Thailand and sales across several global regions.

The next disclosed milestones are the October 19 closing date, October 21 allotment, October 22 demat transfer and refund initiation, and the proposed October 23 listing on BSE and NSE. Investors should review the final offer documents for the definitive offer structure and any additional financial disclosures before making an investment decision.